手术预防性抗菌药物持续时间与类型与抗菌药物相关不良事件的关联
该多中心全国回顾性队列研究纳入79 058例接受心脏、骨科全关节置换、结直肠和血管手术的患者,分析预防性抗菌药物持续时间与手术部位感染(SSI)、急性肾损伤(AKI)和艰难梭菌感染的关系。结果显示,预防持续时间与SSI无关,但每增加一天预防,AKI和艰难梭菌感染风险呈持续时间依赖性增加。
要点
- 延长预防性抗菌药物持续时间不降低SSI风险。
- 预防每增加一天,AKI和艰难梭菌感染风险递增。
- 万古霉素使用是AKI的显著危险因素。
核心结论
- 增加抗菌药物预防持续时间与AKI和艰难梭菌感染风险升高呈持续时间依赖性关联,延长持续时间未进一步减少SSI。
研究设计与样本
- 多中心全国回顾性队列研究,纳入2008年10月1日至2013年9月30日期间接受心脏、骨科全关节置换、结直肠和血管手术并接受计划人工审核的患者,共79 058例。
主要发现
- 按手术类型分层并调整协变量后,SSI与预防持续时间无关。
- 心脏手术中,预防24-<48小时、48-<72小时、≥72小时的AKI调整比值比分别为1.03(95%CI 0.95-1.12)、1.22(95%CI 1.08-1.39)、1.82(95%CI 1.54-2.16)。
- 非心脏手术中,预防24-<48小时、48-<72小时、≥72小时的AKI调整比值比分别为1.31(95%CI 1.21-1.42)、1.72(95%CI 1.47-2.01)、1.79(95%CI 1.27-2.53)。
- 艰难梭菌感染风险呈类似持续时间依赖性关联:24-<48小时aOR 1.08(95%CI 0.89-1.31),48-<72小时aOR 2.43(95%CI 1.80-3.27),≥72小时aOR 3.65(95%CI 2.40-5.53)。
- 万古霉素使用是AKI的显著危险因素:心脏手术aOR 1.17(95%CI 1.10-1.25),非心脏手术aOR 1.21(95%CI 1.13-1.30)。
临床怎么用
- 应限制术后预防性抗菌药物持续时间,以降低AKI和艰难梭菌感染风险而不增加SSI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefits of antimicrobial prophylaxis are limited to the first 24 hours postoperatively. Little is known about the harms associated with continuing antimicrobial prophylaxis after skin closure. OBJECTIVE: To characterize the association of type and duration of prophylaxis with surgical site infection (SSI), acute kidney injury (AKI), and Clostridium difficile infection. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, national retrospective cohort study, all patients within the national Veterans Affairs health care system who underwent cardiac, orthopedic total joint replacement, colorectal, and vascular procedures and who received planned manual review by a trained nurse reviewer for type and duration of surgical prophylaxis and for SSI from October 1, 2008, to September 30, 2013, were included. Data were analyzed using multivariable logistic regression, with adjustments for covariates determined a priori to be associated with the outcomes of interest. Data were analyzed from December 2016 to December 2018. EXPOSURES: Duration of postoperative antimicrobial prophylaxis (<24 hours, 24-<48 hours, 48-<72 hours, and ≥72 hours). MAIN OUTCOMES AND MEASURES: Surgical site infection, AKI, and C difficile infection. RESULTS: Of the 79 058 included patients, 76 109 (96.3%) were men, and the mean (SD) age was 64.8 (9.4) years. Among 79 058 surgical procedures in the cohort, all had SSI and C difficile outcome data available; 71 344 (90.2%) had AKI outcome data. After stratification by type of surgery and adjustment for age, sex, race, diabetes, smoking, American Society of Anesthesiologists score greater than 2, methicillin-resistant Staphylococcus aureus colonization, mupirocin, type of prophylaxis, and facility factors, SSI was not associated with duration of prophylaxis. Adjusted odds of AKI increased with each additional day of prophylaxis (cardiac procedure: 24-<48 hours: adjusted odds ratio [aOR], 1.03; 95% CI, 0.95-1.12; 48-<72 hours: aOR, 1.22; 95% CI, 1.08-1.39; ≥72 hours: aOR, 1.82; 95% CI, 1.54-2.16; noncardiac procedure: 24-<48 hours: aOR, 1.31; 95% CI, 1.21-1.42; 48-<72 hours: aOR, 1.72; 95% CI, 1.47-2.01; ≥72 hours: aOR, 1.79; 95% CI, 1.27-2.53). The risk of postoperative C difficile infection demonstrated a similar duration-dependent association (24-<48 hours: aOR 1.08; 95% CI, 0.89-1.31; 48-<72 hours: aOR, 2.43; 95% CI, 1.80-3.27; ≥72 hours: aOR, 3.65; 95% CI, 2.40-5.53). The unadjusted numbers needed to harm for AKI after 24 to less than 48 hours, 48 to less than 72 hours, and 72 hours or more of postoperative prophylaxis were 9, 6, and 4, respectively; and 2000, 90, and 50 for C difficile infection, respectively. Vancomycin receipt was also a significant risk factor for AKI (cardiac procedure: aOR, 1.17; 95% CI, 1.10-1.25; noncardiac procedure: aOR, 1.21; 95% CI, 1.13-1.30). CONCLUSIONS AND RELEVANCE: Increasing duration of antimicrobial prophylaxis was associated with higher odds of AKI and C difficile infection in a duration-dependent fashion; extended duration did not lead to additional SSI reduction. These findings highlight the notion that every day matters and suggest that stewardship efforts to limit duration of prophylaxis have the potential to reduce adverse events without increasing SSI.
引用
- Branch-Elliman W, O'Brien W, Strymish J, et al. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. JAMA Surg. 2019. PMID: 31017647. doi:10.1001/jamasurg.2019.0569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。